The dark side of semaglutide: what the clinical evidence actually shows

What the STEP 1 trial data revealed about adverse effects

The STEP 1 trial, published in the New England Journal of Medicine and involving over 1,900 adults with obesity, is the largest controlled dataset we have for semaglutide 2.4mg. The efficacy headline (around 15% average body weight reduction over 68 weeks) tends to dominate coverage. Less cited is what happened on the adverse-event side.

Gastrointestinal reactions were by far the most common reason participants discontinued. Nausea affected roughly 44% of those on semaglutide versus 16% on placebo. Vomiting, diarrhoea and constipation all occurred at meaningfully higher rates in the active group. For most people these effects were worst in the first few weeks after a dose increase, then eased. For a smaller subset they were severe enough to stop treatment entirely.

That distinction matters. A question our prescribers hear most weeks is whether side effects mean the medicine is harming you or just adjusting your system. In the majority of cases it is the latter, but the minority who experience severe or persistent symptoms need medical assessment, not reassurance from a forum. If you want a fuller picture of what semaglutide actually is and how it works inside the body before focusing on its risks, the mechanism page covers that ground in detail.

The serious risks the MHRA wants patients to know about

In January 2026 the MHRA published a Drug Safety Update drawing attention to acute pancreatitis as a known risk of the entire GLP-1 class, including semaglutide. The warning was not new (pancreatitis had already appeared in prescribing information) but the formal communication reflected accumulating real-world reports and was intended to sharpen awareness among patients and clinicians alike.

The key symptom pattern is severe, persistent abdominal pain that may radiate through to the back, with or without vomiting. This is not the ordinary nausea of early treatment; it is different in character and requires urgent medical attention. The MHRA's Yellow Card scheme allows patients to report suspected adverse effects directly, and doing so contributes to ongoing safety monitoring.

Other serious but less common concerns include gallbladder problems (gallstones and cholecystitis appear at higher rates in trials), kidney injury secondary to severe dehydration from vomiting, and (in people with diabetic retinopathy) the possibility of vision changes. There are also reports of mood changes and, in a smaller number of cases, thoughts of self-harm; anyone experiencing low mood or mental health changes during treatment should contact their prescriber promptly. The full side-effect picture for the injection form is covered on the semaglutide side effects page.

The practical dark side: what gets less clinical attention

Beyond the reportable adverse events, there are aspects of semaglutide treatment that are less often framed as risks but matter in practice. Muscle loss is one. GLP-1 medicines suppress appetite broadly; without deliberate attention to protein intake and resistance exercise, a meaningful portion of the weight lost can come from lean mass rather than fat. Trials show this happens and it is not captured in the headline percentage figure.

Withdrawal effects are another. Semaglutide is not licensed for lifelong use under NICE's criteria for NHS prescribing, the recommendation specifies a maximum of two years within a specialist service, as set out in NICE's appraisal TA875. When treatment ends, appetite typically returns. Studies suggest a substantial proportion of weight returns within a year of stopping if lifestyle changes haven't been sustained in parallel.

There is also the matter of what's not yet known. Semaglutide's long-term safety profile beyond four to five years in large populations is still accumulating. If you want to understand the fuller picture of these concerns, our page on the dark side of Wegovy explores some of these broader considerations, and if you're specifically weighing up what the downsides of Wegovy are before committing to treatment, that page brings together the key trade-offs in one place. Cost and access add their own pressures, private prescriptions carry a financial commitment; if you're comparing options, the Wegovy cost page sets out what typical UK pricing looks like and what an honest total usually includes.

What good clinical oversight looks like, and why it changes the risk picture

None of the risks above are arguments against semaglutide as a medicine. They are arguments for taking it under proper supervision. The NHS's own guidance on weight-management injections emphasises that patients should be supported with regular clinical review, lifestyle input and clear guidance on when to seek urgent help.

A private route through a regulated pharmacy can deliver the same standard of oversight, provided the clinical infrastructure is genuinely there. That means a prescriber who reviews your case personally before every supply, checks for contraindications including oral contraceptive interactions (tirzepatide carries a specific four-week window; for semaglutide the interaction evidence is less clear-cut, but the conversation is still worth having), and is reachable when something changes. Our clinical team and the structure of our service are designed around exactly that accountability.

Semaglutide is a serious medicine with a meaningful side-effect profile. Used carefully, with eyes open and a prescriber in your corner, that profile is navigable for most people. If you'd like a clinical assessment of whether it's appropriate for you, start your free consultation and our prescribers will review your case the same day.